Diabetes Care

Pop Quiz: Finerenone and Hyperkalemia

James Matera, DO
Practicing Nephrologist, Senior Vice President for Medical Affairs, and Chief Medical Officer
CentraState Medical Center, Freehold, New Jersey

In 2021, the results of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial were published. Finerenone is a selective, mineralocorticoid antagonist with positive impacts on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).1 Finerenone was added to supplement standard therapy with renin-angiotensin-aldosterone system inhibitor (RAASi) agents. FIDELIO-DKD trial investigators examined finerenone’s impact on cardiovascular outcomes in patients with and without history of atherosclerotic cardiovascular disease.2


  1. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.
  2. Filippatos G, Anker SD, Agarwal R, et all; FIDELIO-DKD Investigators. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540-552.